Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus erlotinib in rash-positive metastatic pancreatic cancer with good risk factors
2011-005471-17Phase 2Completed
- Sponsor
- LMU Klinikum
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in pancreatic adenocarcinoma (PDAC), sponsored by LMU Klinikum. Started Jan 2012; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2011-005471-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005471-17.